Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 30, 2026.

Patient-derived xenografts and organoids model therapy response in prostate cancer

Sofia Karkampouna, Federico La Manna, Andrej Benjak and 23 more (opens in a new tab)

Nature Communications · 2021 · CC BY

doi:10.1101/2020.03.17.994350 (opens in a new tab)

Abstract

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe an androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1 -like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.

References 70

  1. 1.

    Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356-387.

    Not in our library10.1016/j.ejca.2018.07.005 (opens in a new tab)

  2. 2.

    Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014;371:424-433.

    Not in our library10.1056/nejmoa1405095 (opens in a new tab)

  3. 3.

    de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011;364:1995-2005.

    Not in our library10.1056/nejmoa1014618 (opens in a new tab)

  4. 4.

    Byrne AT, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer. 2017;17:254-268.

    Not in our library10.1038/nrc.2016.140 (opens in a new tab)

  5. 5.

    Wang Y, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005;64:149-159.

    Not in our library10.1002/pros.20225 (opens in a new tab)

  6. 6.

    Wetterauer C, et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice. Prostate. 2015;75:585-592.

    Not in our library10.1002/pros.22939 (opens in a new tab)

  7. 7.

    Navone NM, et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018;78:1262-1282.

    Not in our library10.1002/pros.23701 (opens in a new tab)

  8. 8.

    Lin D, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014;74:1272-1283.

    Not in our library10.1158/0008-5472.can-13-2921-t (opens in a new tab)

  9. 9.

    Pauli C, et al. Personalized In vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462-477.

    Not in our library10.1158/2159-8290.cd-16-1154 (opens in a new tab)

  10. 10.

    Raheem O, et al. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J. Transl. Med. 2011;9:185.

    Not in our library10.1186/1479-5876-9-185 (opens in a new tab)

  11. 11.

    Williams ES, et al. Generation of prostate cancer patient derived xenograft models from circulating tumor cells. J. Vis. Exp. 2015;105:53182.

    Not in our library10.3791/53182 (opens in a new tab)

  12. 12.
    Patient derived organoids to model rare prostate cancer phenotypes · 2018
    No notice
  13. 13.

    Nguyen HM, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an­­d serve as models for evaluating cancer therapeutics. Prostate. 2017;77:654-671.

    Not in our library10.1002/pros.23313 (opens in a new tab)

  14. 14.

    Navone NM, et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018;78:1262-1282.

    Not in our library10.1002/pros.23701 (opens in a new tab)

  15. 15.

    Palanisamy N, et al. The MD Anderson Prostate Cancer Patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin. Cancer Res. 2020;26:4933-4946.

    Not in our library10.1158/1078-0432.ccr-20-0479 (opens in a new tab)

  16. 16.

    Priolo C, et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 2010;176:1901-1913.

    Not in our library10.2353/ajpath.2010.090873 (opens in a new tab)

  17. 17.

    Klein KA, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 1997;3:402-408.

    Not in our library10.1038/nm0497-402 (opens in a new tab)

  18. 18.
    Application of Cancer Organoid Model for Drug Screening and Personalized Therapy · 2019
    No notice
  19. 19.
    Xenograft and organoid model systems in cancer research · 2019
    No notice
  20. 20.

    Granat LM, et al. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology. Anim. Models Exp. Med. 2019;2:150-161.

    Not in our library10.1002/ame2.12077 (opens in a new tab)

  21. 21.

    Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926.

    Not in our library10.1126/science.aao2774 (opens in a new tab)

  22. 22.

    McCulloch DR, et al. BM18: a novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis. Prostate. 2005;65:35-43.

    Not in our library10.1002/pros.20255 (opens in a new tab)

  23. 23.

    Craft N, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030-5036.

    Not in our library

  24. 24.

    Chakraborty G. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. 2020;26:2047.

    Not in our library10.1158/1078-0432.ccr-19-1570 (opens in a new tab)

  25. 25.
    Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer · 2014
    No notice
  26. 26.
    The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact · 2019
    No notice
  27. 27.

    Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.

    Not in our library10.1038/nature12477 (opens in a new tab)

  28. 28.

    Popova T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454-5462.

    Not in our library10.1158/0008-5472.can-12-1470 (opens in a new tab)

  29. 29.

    Niu B, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015-1016.

    Not in our library10.1093/bioinformatics/btt755 (opens in a new tab)

  30. 30.

    Abida, W., et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. 2018.

    Not in our library10.1001/jamaoncol.2018.5801 (opens in a new tab)

  31. 31.

    Barata P, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J. Immunother. Cancer. 2020;8:e001065.

    Not in our library10.1136/jitc-2020-001065 (opens in a new tab)

  32. 32.
    Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer · 2018
    No notice
  33. 33.

    Rabinovich GA, Conejo-García JR. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 2016;428:3266-3281.

    Not in our library10.1016/j.jmb.2016.03.021 (opens in a new tab)

  34. 34.

    O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019;16:151-167.

    Not in our library10.1038/s41571-018-0142-8 (opens in a new tab)

  35. 35.

    Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215-1228.

    Not in our library10.1016/j.cell.2015.05.001 (opens in a new tab)

  36. 36.

    Grasso CS, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239.

    Not in our library10.1038/nature11125 (opens in a new tab)

  37. 37.
    SPOP mutation leads to genomic instability in prostate cancer · 2015
    No notice
  38. 38.

    Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011-1025.

    Not in our library10.1016/j.cell.2015.10.025 (opens in a new tab)

  39. 39.

    Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012;44:685-689.

    Not in our library10.1038/ng.2279 (opens in a new tab)

  40. 40.

    Rescigno P, et al. Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer. J. Clin. Oncol. 2018;36:5064-5064.

    Not in our library10.1200/jco.2018.36.15_suppl.5064 (opens in a new tab)

  41. 41.

    Augello MA, et al. CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell. 2019;35:817-819.

    Not in our library10.1016/j.ccell.2019.04.012 (opens in a new tab)

  42. 42.

    Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 2013;31:1748-1757.

    Not in our library10.1200/jco.2012.43.1882 (opens in a new tab)

  43. 43.

    Risbridger GP, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 2015;67:496-503.

    Not in our library10.1016/j.eururo.2014.08.007 (opens in a new tab)

  44. 44.
    Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories · 2017
    No notice
  45. 45.

    Vesprini D, et al. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can. Urol. Assoc. J. = J. Assoc. Urol. Can. 2011;5:E31-E35.

    Not in our library10.5489/cuaj.10080 (opens in a new tab)

  46. 46.

    Ma Y, et al. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med. Genet. 2018;19:185-185.

    Not in our library10.1186/s12881-018-0703-9 (opens in a new tab)

  47. 47.

    Prtilo A, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J. Urol. 2005;174:1814-1818.

    Not in our library10.1097/01.ju.0000176796.47988.64 (opens in a new tab)

  48. 48.

    Graham LS, et al. Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLoS ONE. 2020;15:e0233260-e0233260.

    Not in our library10.1371/journal.pone.0233260 (opens in a new tab)

  49. 49.

    Deng G, et al. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br. J. Cancer. 2002;86:574-579.

    Not in our library10.1038/sj.bjc.6600148 (opens in a new tab)

  50. 50.

    Kane MF, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808-811.

    Not in our library

  51. 51.

    Uchida T, et al. Microsatellite instability in prostate cancer. Oncogene. 1995;10:1019-1022.

    Not in our library

  52. 52.

    Egawa S, et al. Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res. 1995;55:2418-2421.

    Not in our library

  53. 53.

    Hempelmann JA, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J. Immunother. Cancer. 2018;6:29-29.

    Not in our library10.1186/s40425-018-0341-y (opens in a new tab)

  54. 54.

    Abida W, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5:471-478.

    Not in our library10.1001/jamaoncol.2018.5801 (opens in a new tab)

  55. 55.

    Gao D, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176-187.

    Not in our library10.1016/j.cell.2014.08.016 (opens in a new tab)

  56. 56.

    Drost J, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 2016;11:347-358.

    Not in our library10.1038/nprot.2016.006 (opens in a new tab)

  57. 57.

    Beshiri ML, et al. A PDX/Organoid Biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin. Cancer Res. 2018;24:4332-4345.

    Not in our library10.1158/1078-0432.ccr-18-0409 (opens in a new tab)

  58. 58.

    Karkampouna S, et al. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J. Pathol. 2018;245:297-310.

    Not in our library10.1002/path.5083 (opens in a new tab)

  59. 59.

    Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology—patient and health systems opportunities. Nat. Rev. Clin. Oncol. 2015;12:732.

    Not in our library10.1038/nrclinonc.2015.169 (opens in a new tab)

  60. 60.

    Sridhar SS, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am. J. Clin. Oncol. 2010;33:609-613.

    Not in our library10.1097/coc.0b013e3181beac33 (opens in a new tab)

  61. 61.

    Guerin O, et al. EGFR targeting in hormone-refractory prostate cancer: current appraisal and prospects for treatment. Pharmacology. 2010;3:2238-2247.

    Not in our library10.3390/ph3072238 (opens in a new tab)

  62. 62.

    Beardsley EK, et al. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Investig. New Drugs. 2012;30:1652-1659.

    Not in our library10.1007/s10637-011-9722-5 (opens in a new tab)

  63. 63.

    Zurita AJ, et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann. Oncol. 2012;23:688-694.

    Not in our library10.1093/annonc/mdr349 (opens in a new tab)

  64. 64.

    Kim IW, Kim JH, Oh JM. Screening of drug repositioning candidates for castration resistant prostate cancer. Front. Oncol. 2019;9:661.

    Not in our library10.3389/fonc.2019.00661 (opens in a new tab)

  65. 65.

    Tan FH, et al. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. OncoTargets Ther. 2019;12:635-645.

    Not in our library10.2147/ott.s189391 (opens in a new tab)

  66. 66.

    Cortes JE, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393-404.

    Not in our library10.1182/blood-2016-09-739086 (opens in a new tab)

  67. 67.

    Sanford D, et al. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 2015;100:e494-e495.

    Not in our library10.3324/haematol.2015.132845 (opens in a new tab)

  68. 68.
    Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening · 2019
    No notice
  69. 69.

    Nuciforo S, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018;24:1363-1376.

    Not in our library10.1016/j.celrep.2018.07.001 (opens in a new tab)

  70. 70.
    A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids · 2019
    No notice

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.